routes. We offer over 150 bulk actives manufactured at USFDA/UK MHRA approved sites. We seek out-licensing opportunities for our speciality generics, super generics, and bulk drugsfor global markets.MANUFACTURINGWith worldclass technology and a team of strong professionals, we have built sites and systemsthat meet the most stringent international manufacturing standards. Expert quality teamsensure that systems and processes remain in compliance with the latest standards. A number ofour plants hold approvals from the USFDA and the UK MHRA. APIs and Dosage forms are madein 19 sites across India, US, Hungary and Bangladesh.FormulationWe make speciality formulations across a range of dosage forms- oral, injectable and deliverysystem based.APIWe make speciality APIs including peptides, steroids, hormones and anticancers atinternationally approved worldclass sites.Quality Policy9| P a g e
Regularly updated systems, procedures and an expert team support a stringent quality policy.Environmental PolicyAt Sun Pharma, a concern for safety and the environment is part of our plans.GROUP COMPANIESCaraco Pharmaceutical LaboratoriesBased in Detroit, Michigan, Caraco develops, manufactures, market and distributes generic andprivate label pharmaceuticals* and markets them throughout the United States. Thecorporation's present portfolio consists of a number of products in various strengths andpackage sizes, across a variety of therapeutic segments, including epilepsy and hypertension.For the most recent year ending March 2008, Caraco had sales of over $350 mill.Caraco's manufacturing facility and executive offices were constructed in 1991, after a $9.1million loan from the Economic Development Corporation of the city of Detroit. Since August1997, capital infusions and loans have primarily come from Sun Pharma. Sun Pharma's investment in and support of Caraco has resulted in, since the second quarter of2002, Caraco achieving the sales to support its operations. As on March 2008, Sun Pharma ownsapprox 76% on a diluted basis of the outstanding common shares of Caraco. Sun Pharma hastwo R&D centers in Baroda and Mumbai, where development work for generics is done.Sun Pharmaceutical Industries Inc. (SPI) Sun Pharmaceutical Industries Inc is a Michigan Corporation and a wholly owned subsidiary ofSun Pharmaceutical Industries Ltd, India. In the second half of 2004, Sun Pharma acquired the trademarks, manufacturing know-how andother intellectual property of certain pharmaceutical products from Women's First Healthcare,Inc, which was under bankruptcy proceedings. On completion of the acquisition in December2004, these products were assigned to Sun Pharma Inc.In December 2005, Sun Pharma Inc completed the purchase of dosage form manufacturingoperations of Able Labs in the US for USD 23.15 million from the US Bankruptcy Court of the10| P a g e
District of New Jersey, Trenton. A plant spread over 35,000 sq ft, in Bryan, Ohio, manufacturesliquids, creams, and ointments. This plant was purchased from Valeant Pharma.